1Maschio G, Alberti D, Janin G, et al. Effect of the angiotensinconverting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med, 1996,334:939-945.
2Brenner BM, Cooper ME, Jeeuw DK, et al. Reduction of endpoints in nom-insulin-dependent diabetes mellitus with angiotensin Ⅱ antagonist losartan. N Engl J Med , 2001,345:861-869.
3Ravid M, Lang R, Rachmani R, et al. Long term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulindependent diabetes mellitus. A 7-year follow up study. Arch Intern Med, 1996,156:286-289.
4Keane WF, Eknoyan G. Proteinuria, albuminuria, risk,assessment, detection, elimination ( PARADE ) : a poisition paper of the National Kidney Fundation. Am J Kidney Dis, 1999,33:1004-1010.
5Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitorassocisled elevations in serum creatinine:Is this a cause for concern?Arch Intern Med, 2000,160:685-693.
6Garey RM, Wang ZQ, Siragy HM. Role of the angiotensin type :2 receptor in the regulation of blood pressure and renal function.Hypertension, 2000,35 : 155-163.
7Prage M, Hernandez E, Montoyo C, et al. Long-term beneficial effect of angiotensin converting enzyme inhibition in patients with nephritis. Am J Nephrol, 1993,13:376-380.
8Bumier M, Rutschmann B, Nussberger J, et al. Suit-dependent renal effects of an anglotensin Ⅱ antagonist in healthy subjects.Hypertension, 1993,22:339-347.
9Tall MW,Brenner BM.Renalprotective benefits of RAS inhibition:from ACEI to agniotensin Ⅱ antagonists.Kidney Int,2000,57:1803
10Tarif N,Bakris GL,Angiotensin Ⅱ receptor blockade and progression of nondiabetic-mediated renal disease.Kidney Int,1997,52(Suppl 63):67s
